Nope. No mention of these specific symptoms...seems as if they just measured the presence of thyroiditis antibodies. Perhaps the final draft will contain more details on other symptoms exhibited by the test/control groups.
Here's the summary from the paper:
Context: Hashimoto’s thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found
in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of
Hashimoto’s thyroiditis.
Objective: The effects of anatabine in patients with Hashimoto’s thyroiditis.
Design, Setting, Patients, and Intervention: Double-blind, randomized, placebo-controlled multisite
study.Atotal of 146 patients (70 treated with anatabine, and 76 placebo) completed the study.
Approximately 50% of patients in each group were on levothyroxine medication. Anatabine lozenges
(9–24 mg/day) or placebo, each containing vitamins A and D3, were administered orally 3
times a day for three months.
Main Outcome Measures: Assessment of serum thyroid peroxidase antibodies (TPOAb) and thyroglobulin
antibodies (TgAb). Safety was assessed though adverse events (AEs), clinical laboratory
evaluations, and vital sign measurements.
Results: Anatabine treated patients had a significant reduction in absolute serum TgAb levels from
baseline by study end relative to those on placebo (p0.027); however, there were no significant
changes or differences in treatment group means for TPOAb or TgAb. Mean (SD) TgAb values
decreased by 46.2 (101.1) and 3.9 (83.9) WHO units for the anatabine and placebo groups,
respectively. Significantly more patients had a 20% drop in TgAb in the anatabine than placebo
group (p0.023). Overall the anatabine supplement was safe and well tolerated, although significantly
(p0.05) more patients in the anatabine group reported AEs.
Conclusions: These results demonstrate an immunological effect of anatabine on TgAb levels.
Further studies are warranted to dissect longer-term effects and possible actions of anatabine on
the course of Hashimoto’s thyroiditis.
AI
